Updates in Treatment Strategies for Hodgkin Lymphoma

Most patients with Hodgkin lymphoma experience favorable outcomes after therapy, but some patients experience relapse and many others experience treatment-related toxicities. To combat these issues, it is important to have therapies that are effective and less toxic. Current treatment strategies are integrating approaches aimed at decreasing chemotherapy and radiotherapy doses, and the long-term effects of these approaches are continually being evaluated. Emerging clinical studies are investigating the effects of combining targeted therapies, largely in the form of immunotherapies, with standard chemotherapy options. It is difficult for clinicians to stay current with the research.  An awareness of the results and impact of these on-going clinical trials will help oncology clinicians determine how to incorporate these novel agents and approaches into the standard of care for patients with Hodgkin lymphoma.

 

This information was originally presented at the NCCN 2019 Annual Congress: Hematologic Malignancies™  held in San Francisco, CA, on September 27-28, 2019.

Target Audience

This educational program is designed to meet the educational needs of the interprofessional oncology care team, including: physicians/oncologists, nurses, physician assistants, pharmacists, and other healthcare professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Summarize current standard treatment options for patients with classic Hodgkin lymphoma.
  • Identify novel therapeutic agents or regimens and how to incorporate them into the management of patients with advanced or relapsed or refractory Hodgkin lymphoma.
  • Outline potential strategies to consider when developing treatment plans for patients with Hodgkin lymphoma, including prognostic markers and sequence of treatment.
Additional information
Supporters: 


This activity is supported by educational grants from: 

  • Agios Pharmaceuticals
  • AstraZeneca
  • BeiGene, Ltd.
  • Celgene Corporation
  • Coherus Biosciences
  • Genentech
  • Jazz Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Seattle Genetics, Inc.
  • Servier Pharmaceuticals, LLC
  • Takeda Oncology

This activity is supported by educational funding provided by Amgen.

This activity is supported by an independent educational grant from AbbVie.

This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

 

Course summary
Available credit: 
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.54 ANCC contact hours
  • 0.50 Participation
Course opens: 
11/01/2019
Course expires: 
10/31/2020
Cost:
$0.00


Ranjana H. Advani, MD
Stanford Cancer Institute

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures 
The faculty listed below discloses the following relevant financial relationships:

Ranjana H. Advani, MD
 Agensys, Inc.: Grant/Research Support
 AstraZeneca Pharmaceuticals LP: Consulting Fee; Scientific Advisor
 Bayer HealthCare: Consulting Fee; Scientific Advisor
 Celgene Corporation: Grant/Research Support
 Cell Medica: Consulting Fee; Scientific Advisor
 Forty Seven, Inc.: Grant/Research Support
 Genentech, Inc./Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support; Scientific Advisor
 Gilead Sciences, Inc.: Consulting Fee; Scientific Advisor
 Janssen Pharmaceutica Products, LP: Grant/Research Support
 Kite Pharma: Consulting Fee; Scientific Advisor
 Kura Oncology, Inc.: Grant/Research Support
 Kyowa Hakko Kirin Co., Ltd.: Consulting Fee; Scientific Advisor
 Merck & Co., Inc.: Grant/Research Support
 Millennium Pharmaceuticals, Inc.: Grant/Research Support
 Pharmacyclics: Grant/Research Support
 Regeneron Pharmaceuticals, Inc.: Grant/Research Support
 Seattle Genetics, Inc.: Consulting Fee; Grant/Research Support; Scientific Advisor
 Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Scientific Advisor 

NCCN Staff Disclosures 

The NCCN Activity Planning staff listed below discloses no relevant financial relationships: 
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Sarah Sinclair; Kathy Ann Smith, CHCP 

The NCCN Leadership listed below discloses no relevant financial relationships: 
Robert W. Carlson, MD; Wui-Jin Koh, MD; Gary J. Weyhmuller, MBA, SPHR  

The NCCN Clinical staff listed below discloses no relevant financial relationships: 
Jennifer L. Burns, BS;  Ndiya Ogba, PhD

 In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physicians 
NCCN designates this enduring activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurses 
NCCN designates this educational activity for a maximum of .54 contact hours. 

Pharmacists
NCCN designates this knowledge-based continuing education activity for .5 contact hours (0.05 CEUs) of continuing education credit. UAN: JA4008196-0000-19-089-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Catergory 1 CME credit for activities planned in accordance with AAPA CME criteria. This activity is designated for .5 AAPA Catergory 1 CME credits. Approval is valid until October 31, 2020. PAs should only claim credit commensurate with the extent of their participation. 

Available Credit

  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.54 ANCC contact hours
  • 0.50 Participation

Accreditation Period

Course opens: 
11/01/2019
Course expires: 
10/31/2020

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: